ATE256186T1 - Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten - Google Patents

Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten

Info

Publication number
ATE256186T1
ATE256186T1 AT97940771T AT97940771T ATE256186T1 AT E256186 T1 ATE256186 T1 AT E256186T1 AT 97940771 T AT97940771 T AT 97940771T AT 97940771 T AT97940771 T AT 97940771T AT E256186 T1 ATE256186 T1 AT E256186T1
Authority
AT
Austria
Prior art keywords
vegf145
derivatives
novel
protein products
vegf
Prior art date
Application number
AT97940771T
Other languages
English (en)
Inventor
Gera Neufeld
Eli Keshet
Israel Vlodavsky
Zoya Poltorak
Original Assignee
Technion Res & Dev Co Ltd
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Co Ltd, Collateral Therapeutics filed Critical Technion Res & Dev Co Ltd
Application granted granted Critical
Publication of ATE256186T1 publication Critical patent/ATE256186T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97940771T 1996-09-06 1997-09-04 Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten ATE256186T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2553796P 1996-09-06 1996-09-06
US08/784,551 US6013780A (en) 1996-09-06 1997-01-21 VEGF145 expression vectors
PCT/US1997/015471 WO1998010071A1 (en) 1996-09-06 1997-09-04 Angiogenic factor and use thereof in treating cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE256186T1 true ATE256186T1 (de) 2003-12-15

Family

ID=26699889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940771T ATE256186T1 (de) 1996-09-06 1997-09-04 Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten

Country Status (14)

Country Link
US (3) US6013780A (de)
EP (1) EP0925360B1 (de)
JP (1) JP2001500728A (de)
KR (1) KR20000068506A (de)
CN (1) CN1236390A (de)
AT (1) ATE256186T1 (de)
AU (1) AU737898B2 (de)
CA (1) CA2265252C (de)
DE (1) DE69726741T2 (de)
EA (1) EA004646B1 (de)
ES (1) ES2212127T3 (de)
IL (1) IL128727A (de)
NZ (1) NZ334508A (de)
WO (1) WO1998010071A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
NZ505955A (en) * 1998-02-06 2005-04-29 Collateral Therapeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2229788T3 (es) * 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7097832B1 (en) * 1999-03-30 2006-08-29 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US20040131601A1 (en) * 2000-03-30 2004-07-08 Foundry Networks, Inc., A Delaward Corporation Injection of bone marrow-derived cells and medium for angiogenesis
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2373822A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants
EP1183357A2 (de) * 1999-05-20 2002-03-06 Scios Inc. Vaskuläre endothelzellen wachstumsfaktordimere
WO2001049338A1 (en) * 1999-12-30 2001-07-12 Li Wei Pin Controlled delivery of therapeutic agents by insertable medical devices
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
AU2001245734A1 (en) * 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
PT2295070E (pt) 2000-04-12 2015-12-07 Life Sciences Res Partners Vzw Utilização de vegf e homólogos para tratar distúrbios do neurónio
EP1294407A2 (de) * 2000-06-30 2003-03-26 Collateral Therapeutics Zweirekombinante enthaltende zusammensetzungen zur gentherapie und verfahren zur herstellung
US20020111324A1 (en) * 2000-08-17 2002-08-15 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
US6953560B1 (en) * 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US20050142130A1 (en) * 2001-01-04 2005-06-30 Roks Antonius J.M. Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
EP1427432A4 (de) * 2001-08-29 2008-01-23 Regenerx Biopharmaceuticals Verfahren zur heilung oder prävention von entzündungen, schäden und anderen veränderungen, die vor, während oder unmittelbar nach einem myokardinfarkt auftreten, mit thymosin beta 4, analoga, isoformen und anderen derivaten
JP4361791B2 (ja) 2001-08-29 2009-11-11 ジェネンテック・インコーポレーテッド マイトジェン活性を有するＢｖ８核酸及びポリペプチド
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
WO2003101201A1 (en) * 2002-05-30 2003-12-11 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
KR100766952B1 (ko) * 2002-12-09 2007-10-17 주식회사 툴젠 조절성 징크 핑거 단백질
WO2004055156A2 (en) * 2002-12-17 2004-07-01 Technion Research And Development Foundation Ltd. A vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
CA2604441A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR100772424B1 (ko) * 2005-08-05 2007-11-01 박기랑 ⅤＥＧＦ－Ａ，ⅤＥＧＦ－Ｂ，및 ⅤＥＧＦ－Ｃ의 안티센스 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스 및 ⅤＥＧＦＲ 트렁케이티드 솔루블 ｃＤＮＡ를 함유하는 재조합 아데노-연관 바이러스를 포함하는 암의 유전자 치료제
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
SG182170A1 (en) * 2007-06-06 2012-07-30 Domantis Ltd Polypeptides, antibody variable domains and antagonists
US20100087783A1 (en) * 2008-10-07 2010-04-08 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
CN110760542B (zh) * 2019-11-18 2022-07-26 天津大学 一种共表达znf580和vegf165双基因的质粒及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5288846A (en) * 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
DE69523163T2 (de) * 1994-07-20 2002-03-07 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von stabilisierter getrockeneter carboxyesterase
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors

Also Published As

Publication number Publication date
EA004646B1 (ru) 2004-06-24
US6589782B1 (en) 2003-07-08
EP0925360B1 (de) 2003-12-10
ES2212127T3 (es) 2004-07-16
JP2001500728A (ja) 2001-01-23
AU737898B2 (en) 2001-09-06
IL128727A0 (en) 2005-11-20
HK1020756A1 (en) 2000-05-19
CN1236390A (zh) 1999-11-24
NZ334508A (en) 2001-03-30
CA2265252A1 (en) 1998-03-12
WO1998010071A1 (en) 1998-03-12
IL128727A (en) 2007-06-17
US6013780A (en) 2000-01-11
US6583276B1 (en) 2003-06-24
EA199900262A1 (ru) 1999-10-28
KR20000068506A (ko) 2000-11-25
DE69726741D1 (de) 2004-01-22
CA2265252C (en) 2005-04-19
AU4247197A (en) 1998-03-26
DE69726741T2 (de) 2004-09-30
EP0925360A1 (de) 1999-06-30

Similar Documents

Publication Publication Date Title
ATE256186T1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
Lee et al. Impaired wound healing and angiogenesis in eNOS-deficient mice
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
KR950700995A (ko) 조절 신호인 지방체(oil-body) 단백질 시스-요소(cis-element)(OIL-BODY PROTEIN CIS-ELEMENTS AS REGULATORY SIGNALS)
DE69328685D1 (de) Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
BR0016032A (pt) Colágeno
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
FR2805821B1 (fr) Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69820908D1 (de) N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
Ulrich et al. Expression profile of proteins involved in scar formation in the healing process of full‐thickness excisional wounds in the porcine model
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
Becker et al. Effect of the flavonoid (+) cyanidanol-3 on procollagen biosynthesis and transport in normal and ataxia telangiectasia cultured skin fibroblasts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0925360

Country of ref document: EP

REN Ceased due to non-payment of the annual fee